Head-to-head evidence
Ivosidenib vs Olutasidenib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: Mutant IDH1 · full Acute Myeloid Leukemia pipeline
Ivosidenib
Marketed by Servier
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT02074839 (registry estimate)
Olutasidenib
Marketed by Rigel Pharmaceuticals
NCT02719574 · Phase 1/2 · completed
This is a single-arm, open-label study with no randomization, no blinding, and no comparator or control arm, and it is not an extension of a prior randomized trial. All enrolled patients received olutasidenib (alone or with azacitidine/cytarabine), and the Phase 2 primary endpoints are descriptive response/remission rates rather than comparisons against a control. Because there is no control group, the results cannot separate drug effect from natural history or patient selection, so the evidence is weak regardless of the reported response rates.
Next expected readout: January 2027 · NCT07411586 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ivosidenib's landscape · Olutasidenib's landscape